2. Academic Validation
  3. Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy

Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy

  • Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721.
Bartlomiej Borek # 1,  Julita Nowicka # 1,  Anna Gzik # 1,  Marek Dziegielewski # 1,  Karol Jedrzejczak 1,  Joanna Brzezinska 1,  Marcin Grzybowski 1,  Paulina Stanczak 1,  Paulina Pomper 1,  Agnieszka Zagozdzon 1,  Tomasz Rejczak 1,  Krzysztof Matyszewski 1,  Adam Golebiowski 1,  Jacek Olczak 1,  Kamil Lisiecki 1,  Magdalena Tyszkiewicz 1,  Magdalena Kania 1,  Sylwia Piasecka 1,  Anna Cabaj 1,  Paulina Dera 1,  Krzysztof Mulewski 1,  Jacek Chrzanowski 1,  Damian Kusmirek 1,  Elzbieta Sobolewska 1,  Marta Magdycz 1,  Lukasz Mucha 1,  Marek Masnyk 1,  Jakub Golab 2,  Marcin Nowotny 3,  Elzbieta Nowak 3,  Agnieszka Napiorkowska-Gromadzka 3,  Stanislaw Pikul 1,  Radoslaw Jazwiec 4,  Karolina Dzwonek 1,  Pawel Dobrzanski 1,  Michael Meyring 5,  Krzysztof Skowronek 6,  Piotr Iwanowski 1,  Zbigniew Zaslona 1,  Roman Blaszczyk 1
Affiliations

Affiliations

  • 1 Molecure S.A., Warsaw, Poland.
  • 2 Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
  • 3 Laboratory of Protein Structure, International Institute of Molecular and Cell Biology, Warsaw, Poland.
  • 4 Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland.
  • 5 Nuvisan GmbH, Grafing, Germany.
  • 6 Biophysics and Bioanalytics Facility, International Institute of Molecular and Cell Biology, Warsaw, Poland. (RRID:SCR_021630).
  • # Contributed equally.
PMID: 36939275 DOI: 10.1158/1535-7163.MCT-22-0721
Abstract

Pharmacologic inhibition of the controlling immunity pathway Enzymes arginases 1 and 2 (ARG1 and ARG2) is a promising strategy for Cancer Immunotherapy. Here, we report the discovery and development of OATD-02, an orally bioavailable, potent arginases inhibitor. The unique pharmacologic properties of OATD-02 are evidenced by targeting intracellular ARG1 and ARG2, as well as long drug-target residence time, moderate to high volume of distribution, and low clearance, which may jointly provide a weapon against arginase-related tumor immunosuppression and ARG2-dependent tumor cell growth. OATD-02 monotherapy had an antitumor effect in multiple tumor models and enhanced an efficacy of the Other immunomodulators. Completed nonclinical studies and human pharmacokinetic predictions indicate a feasible therapeutic window and allow for proposing a dose range for the first-in-human clinical study in patients with Cancer.

Significance: We have developed an orally available, small-molecule intracellular Arginase 1 and 2 inhibitor as a potential enhancer in Cancer Immunotherapy. Because of its favorable pharmacologic properties shown in nonclinical studies, OATD-02 abolishes tumor immunosuppression induced by both arginases, making it a promising drug candidate entering clinical trials.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z